FIELD: medicine.
SUBSTANCE: invention refers to medicine and aims at early diagnosis of gastric cancer metastases into peritoneum and omentum. During surgery for gastric cancer in tissue of greater omentum and peritoneum by enzyme immunoassay, content of CA-19.9 protein is determined, at its level in gland, equal to 1465.1±181.2 units/g of tissue and level in peritoneum tissue equal to 1234.5±105.6 units/g of tissue, development of these metastases in 4–6 months is predicted.
EFFECT: method enables the stage of surgical removal of the tumor to determine the nature of the further development of the malignant process in patients suffering gastric cancer.
1 cl, 1 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR PREDICTION OF OVARIAN CANCER PERITONEAL PROPAGATION | 2019 |
|
RU2722654C1 |
| METHOD FOR PREDICTION OF DISEASE OUTCOME IN PATIENTS WITH GASTRIC CANCER AFTER SURGICAL MANAGEMENT | 2018 |
|
RU2696054C1 |
| METHOD FOR THE TREATMENT OF PERITONEAL CARCINOMATOSIS IN OVARIAN CANCER | 2021 |
|
RU2745478C1 |
| METHOD FOR COMBINED TREATMENT OF RESECTABLE LOCALLY ADVANCED GASTRIC CANCER WITH PERITONEAL CARCINOMATOSIS APPLYING PERSONALISED SYSTEMIC AND INTRAPERITONEAL CHEMOTHERAPY | 2021 |
|
RU2773100C1 |
| PROGNOSIS METHOD FOR DISEASE PROGRESSION IN PATIENTS WITH GASTROINTESTINAL CANCER AFTER TREATMENT | 2021 |
|
RU2758079C2 |
| METHOD FOR PREDICTION OF CYTOREDUCTIVE SURGERY VOLUME IN PATIENTS WITH ADVANCED OVARIAN CANCER AFTER COMPLETION OF THIRD COURSE OF NEOADJUVANT CHEMOTHERAPY | 2017 |
|
RU2671409C2 |
| TEST SYSTEM “HV2 mtDNA-PCR” FOR PREDICTING THE DEVELOPMENT OF METASTASES IN PATIENTS WITH GASTRIC CANCER | 2017 |
|
RU2683571C1 |
| METHOD FOR DIFFERENTIAL DIAGNOSIS OF ASCITIC-INFILTRATIVE OVARIAN CANCER AND ABDOMINAL TUBERCULOSIS | 2015 |
|
RU2585959C1 |
| METHOD OF COMBINED TREATMENT OF GASTRIC CANCER PATIENTS WITH PERITONEAL CARCINOMATOSIS | 2018 |
|
RU2696534C1 |
| METHOD FOR PREDICTION OF METASTASES DEVELOPMENT IN PATIENTS WITH GASTRIC CANCER | 2016 |
|
RU2624505C1 |
